Qiming Weekly | Qiming Venture Partners Portfolio Companies: Funding and Updates Vol. 18, 2025
Staying with you through milestone moments for Qiming Venture Partners' portfolio companies
Editor's Note: The "Qiming Weekly" column publishes regularly every week, rounding up funding news and development updates from Qiming Venture Partners' portfolio companies.
In the wave of technology and innovation, every step entrepreneurs take deserves to be recorded. Qiming Venture Partners will continue to accelerate and empower entrepreneurs, and we invite you to join us in marking the milestone moments of our portfolio companies.
Corporate ESG
Four Qiming Venture Partners Portfolio Companies Selected for S&P Global's Sustainability Yearbook (China Edition) 2025
Recently, S&P Global's Sustainability Yearbook (China Edition) 2025 was officially released. The yearbook aims to identify and recognize Chinese companies that demonstrate sustainability advantages in industries including biotechnology, healthcare, machinery and electrical equipment, automotive manufacturing, and communications equipment.
Qiming Venture Partners portfolio companies Gan & Lee Pharmaceuticals (603087.SH), Arrail Group (06639.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), and CanSino Biologics (688185.SH, 06185.HK) were selected for the yearbook. Among them, Gan & Lee Pharmaceuticals and Arrail Group were respectively named Best Progress Companies in the biotechnology and healthcare sectors.
Funding News
Jiangling Technology Completes Two Consecutive Rounds Raising Several Hundred Million Yuan
Qiming Venture Partners Leads B+ Round
Recently, leading domestic semiconductor metrology and inspection equipment company Jiangling Technology announced the successful completion of its Series B and B+ financing rounds, with Qiming Venture Partners leading the B+ round. The proceeds will be primarily used for new product R&D and scaled production capacity deployment.
Founded in 2018, Jiangling Technology is dedicated to providing advanced optical metrology and inspection equipment for global semiconductor customers, striving to become a top-tier semiconductor metrology and inspection equipment company in Asia. Through long-term deep cultivation in high technical barrier fields and continuous innovation breakthroughs, Jiangling Technology has successfully achieved independent innovation of multiple high-end metrology and inspection equipment, filling domestic technological gaps in this area.
Jiangling Technology has long focused on the advanced front-end metrology segment of semiconductors. Through sustained technology accumulation and solid customer practice, its core products — critical thin film metrology tools and optical critical dimension metrology tools — are already capable of supporting stable mass production for domestic customers. At the same time, Jiangling Technology has systematically integrated multiple AI-enabled technologies, employing physics-informed self-supervised adaptive scalable neural network architectures combined with machine learning methods for data preprocessing, dimensionality reduction, classification, and prediction. Using self-controllable high-performance parallel computing nodes, the company optimizes metrology precision and tool matching, while advancing AI model data analysis processing and systematic learning capabilities to comprehensively accelerate yield management and control for scarce domestic processes.
Major Partnerships
01/
WeRide and Tencent Cloud Deepen Collaboration
Expanding Robotaxi Commercial Operations and Overseas Markets
Recently, Qiming Venture Partners portfolio company WeRide (NASDAQ:WRD) signed a deepened strategic cooperation agreement with Tencent Cloud to further advance the two parties' long-term deep collaboration in Robotaxi large-scale commercial operations, intelligent driving technology R&D, and overseas market expansion.
Under the agreement, both parties will jointly advance the large-scale commercial operation of L4 autonomous driving Robotaxi, integrating WeRide's Robotaxi services into WeChat's "Travel Services," Tencent Maps, and other applications to bring users a safer, more convenient, and more comfortable autonomous driving travel experience. Tencent will also provide cloud and map data services for WeRide's Robotaxi technology R&D and commercial operations.
For global development, both parties will jointly build intelligent driving solutions targeting overseas markets. WeRide and Tencent Cloud will also deeply collaborate on building a "cloud-map integrated" data-driven platform and tools, and create full-process data compliance solutions to accelerate intelligent driving technology R&D and mass production deployment.
02/
Hesai Technology Secures Exclusive Designation for Great Wall Motor's EV Brand ORA's Next-Generation Models
Recently, Qiming Venture Partners portfolio company Hesai Technology (NASDAQ:HSAI) announced it has secured an exclusive designation for Great Wall Motor's new energy vehicle brand ORA's next-generation models. ORA vehicles equipped with Hesai Technology LiDAR are expected to enter mass production and begin gradual customer delivery within this year.
Going forward, Hesai Technology will continue to work closely with multiple automotive brands under Great Wall Motor, including ORA and WEY, to jointly promote the普及 of LiDAR technology. Through the "invisible airbag," the company will provide more reliable safety redundancy for advanced driver-assistance systems, comprehensively safeguarding driving safety and helping Great Wall Motor achieve further sales breakthroughs.
03/
DeepWay Signs Official Distribution Agreement with Malaysian Partner
Recently, Qiming Venture Partners portfolio company DeepWay formally signed a distribution agreement with its Malaysian partner. This follows the company's entry into the Singapore and Thai markets, representing another strategic layout in Southeast Asia and marking the continued acceleration of DeepWay's internationalization process.
On the day of the signing, the Malaysian partner took a hands-on test drive of DeepWay's right-hand-drive new-energy heavy truck and powered trailer products, giving high marks to the vehicles' range performance, intelligent driving capabilities, and local adaptability. Lin Facai, general manager of DeepWay International, gave a comprehensive overview of the company's advanced capabilities in electrification core technology, intelligent driving, and global service infrastructure. Both sides agreed that this partnership would drive logistics upgrades in the Malaysian market and lay a solid foundation for deeper regional expansion going forward.
04/
Chuhang Technology Forms Joint Venture with Malaysian Company MCE
At the World Expo in Osaka, Japan, Qiming Venture Partners portfolio company Chuhang Technology formally signed a strategic cooperation agreement with Malaysian firm MCE Technologies Sdn Bhd ("MCE").
Under the agreement, Chuhang Technology and MCE will establish a joint venture in Malaysia to jointly invest in building a millimeter-wave radar production line. The joint venture aims to leverage Chuhang Technology's strengths in millimeter-wave radar R&D and manufacturing, combined with MCE's market resources and distribution channels in Southeast Asia, particularly Malaysia, to deepen penetration in global markets.
05/ Elpiscience Enters Clinical Research Strategic Partnership with Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Recently, Qiming Venture Partners portfolio company Elpiscience established a clinical research strategic partnership with Union Hospital, Tongji Medical College, Huazhong University of Science and Technology ("Wuhan Union Hospital").
Wuhan Union Hospital will work closely with Elpiscience on pharmaceutical clinical research projects, actively contributing professional researchers and other support resources for Elpiscience's clinical trial programs, while jointly strengthening pharmaceutical translation platform development and talent exchange. The two parties will integrate and align resources across pharmaceuticals, healthcare, and IT sectors, sharing resources and pursuing collaborative innovation to ensure projects are completed more efficiently and smoothly, continuously optimizing pharmaceutical R&D service platforms to benefit more cancer patients.
06/ Merck & Co. and Antengene Enter Global Clinical Collaboration
Recently, Qiming Venture Partners portfolio company Antengene (06996.HK) announced a global clinical collaboration with Merck & Co. (Merck & Co. is the trade name of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA) to jointly conduct a clinical study evaluating ATG-022 (a CLDN18.2 antibody-drug conjugate) in combination with Merck & Co.'s PD-1 inhibitor KEYTRUDA® (Pembrolizumab) for patients with advanced solid tumors.
ATG-022 holds distinctive advantages in the global development landscape, with existing data supporting meaningful efficacy in gastric cancer patients with high, low, and ultra-low Claudin 18.2 expression. This broad-spectrum anti-tumor activity positions ATG-022 to potentially bring new treatment options to a wider patient population compared to other CLDN18.2-targeted therapies.
07/ Bohe Health and Fudong Muscle & Bone Launch Professional Weight Management Package
Recently, health management platform Bohe Health and Qiming Venture Partners portfolio company Fudong Muscle & Bone announced a partnership. Fudong Muscle & Bone will join the Bohe Health platform to provide users with professional, science-based weight management services.
Through Fudong Muscle & Bone's presence on the Bohe Health platform, the partnership leverages professional medical rehabilitation expertise to deliver comprehensive scientific weight management services for people seeking to lose weight. Drawing on a China NHC-certified rehabilitation therapist team and professional sports medicine assessment systems, the companies have developed distinctive weight management programs.
From "weight-loss joint injury prevention assessments" that guard against joint damage, to "joint injury rehabilitation assessments" for those already injured; from one-on-one customized "medical weight management packages" to "remote monthly plans" that can be completed at home — the offerings comprehensively address diverse user needs across the weight management spectrum.
R&D Progress
01/ Gan & Lee Pharmaceuticals Completes First Patient Dosing in China Phase 1 Clinical Study of GZR102 Injection
Recently, Qiming Venture Partners portfolio company Gan & Lee Pharmaceuticals (603087.SH) announced that its self-developed basal insulin and glucagon-like peptide-1 receptor agonist (GLP-1RA) fixed-ratio combination weekly formulation GZR102 Injection has completed first-patient dosing in a Phase 1 clinical study in overweight adults in China.
This innovative drug combines insulin weekly formulation (GZR4 Injection) and GLP-1RA bofanglutide (development code: GZR18 Injection) in a fixed ratio. Both component drugs, GZR4 Injection and GZR18 Injection, have already undergone thorough dose exploration in Phase 2 clinical trials in type 2 diabetes (T2DM) patients, with favorable safety
02/ InventisBio Completes First Patient Dosing in Phase 2 Study of Novel TYK2 Inhibitor D-2570 for Ulcerative Colitis
Recently, Qiming Venture Partners portfolio company InventisBio (688382.SH) announced that a multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical study evaluating the efficacy and safety of its TYK2 inhibitor D-2570 (Nomelcitinib) in moderate to severe active ulcerative colitis has completed first-patient dosing at Sir Run Run Shaw Hospital, Zhejiang University School of Medicine.
D-2570 (Nomelcitinib) is a novel oral selective TYK2 inhibitor self-developed by InventisBio. It works by selectively binding to the pseudokinase domain JH2 of TYK2, inhibiting TYK2 kinase activity, thereby blocking TYK2-dependent cytokine signal transduction-mediated STAT protein phosphorylation, suppressing inflammatory factor release, and participating in immune modulation.
03/ Bioray Laboratories to Present Latest Data on RD06-03 for Relapsed or Refractory Acute B-Lymphoblastic Leukemia
Recently, Qiming Venture Partners portfolio company Bioray Laboratories announced it will present Phase 1 clinical data on its CD19-targeted allogeneic CAR-T cell product RD06-03 in patients with relapsed or refractory acute B-lymphoblastic leukemia (R/R B-ALL) in poster format at the American Society of Clinical Oncology (ASCO) Annual Meeting.
RD06-03 uses genetic modification to prevent fratricide, graft-versus-host disease (GvHD), and host-versus-graft rejection (HvG) while enhancing anti-tumor activity. RD06-03 can be manufactured in a single batch for multiple patients, enabling "off-the-shelf" availability whenever CAR-T therapy is needed.
04/ Sanegene Bio's siRNA Drug for Complement Diseases Approved for Clinical Trials in China
Recently, Qiming Venture Partners portfolio company Sanegene Bio announced that its independently developed small interfering RNA (siRNA) drug SGB-3383 injection, targeting CFB, has received implied clinical trial approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (acceptance number: CXHL2500238). The drug is indicated for complement-mediated kidney diseases, including IgA nephropathy, C3 glomerulopathy, immune complex-mediated membranoproliferative glomerulonephritis, and atypical hemolytic uremic syndrome.
SGB-3383 is an RNAi therapy targeting Complement Factor B (CFB), delivered to hepatocytes via Sanegene Bio's uniquely innovative next-generation GalNAc liver delivery platform. It treats complement-mediated kidney diseases by suppressing CFB expression in the liver through RNA interference. Preclinical data shows that SGB-3383 significantly and durably reduces CFB levels in the liver and blood, with favorable safety and tolerability profiles. Currently, no complement-targeting siRNA drug has been approved globally. SGB-3383 is poised to become China's first and a world-leading CFB-targeting siRNA drug.
05/ Abbisko Pharma's Irpagratinib Receives Breakthrough Therapy Designation in China for Hepatocellular Carcinoma
Recently, Qiming Venture Partners portfolio company Abbisko Pharma (02256.HK) announced that its independently developed highly selective small-molecule FGFR4 inhibitor irpagratinib (Irpagratinib/ABSK011) has received Breakthrough Therapy Designation from the Center for Drug Evaluation (CDE) of the National Medical Products Administration for the treatment of hepatocellular carcinoma (HCC). Irpagratinib is the first drug to employ targeted molecular biomarkers for precision treatment of hepatocellular carcinoma.
Currently, patients with advanced or unresectable hepatocellular carcinoma lack effective treatment options following ICI and mTKI therapy. Patients with FGF19 overexpression often have poorer prognoses, creating an urgent need for new therapeutic alternatives. The Breakthrough Therapy Designation for irpagratinib will help accelerate subsequent regulatory filings and approvals, bringing new hope to patients with substantial unmet medical needs. Abbisko Pharma's pivotal registrational clinical study for irpagratinib has officially launched at Tongji Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology and Nanjing Tianyinshan Hospital.
06/ Abbisko Pharma to Present Phase 3 MANEUVER Study Results for Pimicotinib in Tenosynovial Giant Cell Tumor
Recently, Qiming Venture Partners portfolio company Abbisko Pharma (02256.HK) announced it will present Phase 3 study results for its independently developed small-molecule CSF-1R inhibitor pimicotinib in tenosynovial giant cell tumor (TGCT) — covering efficacy, safety, and patient-reported outcomes — as an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
Pimicotinib has received Breakthrough Therapy Designation (BTD) from the National Medical Products Administration (NMPA) and the FDA for the treatment of unresectable TGCT, as well as Priority Medicines (PRIME) designation from the European Medicines Agency (EMA).
07/
Shize Biotech's Universal Cell Therapy for Major Disease Spinal Cord Injury Receives Formal Approval from Chinese and U.S. Regulators for Registrational Clinical Trials
Recently, Qiming Venture Partners portfolio company Shize Biotech officially announced that its independently developed "world's first" allogeneic universal "off-the-shelf" iPSC-derived subtype-specific neural cell therapy has received complete, no-questions-asked approval from both the National Medical Products Administration (NMPA) and the FDA for registrational clinical trials in the treatment of major neurological disease spinal cord injury.
As the "world's first" registrational clinical trial for regenerative treatment of spinal cord injury using regenerative spinal cord region-specific neural progenitor cell therapy, the study will be led by Professor Rong Limin, President of the Third Affiliated Hospital of Sun Yat-sen University and a top expert in spinal cord injury diagnosis and treatment, as the principal clinical center and overall clinical lead. Professor Liu Jing, Party Secretary of the First Affiliated Hospital of Dalian Medical University and President of the Dalian Stem Cell and Precision Medicine Innovation Research Institute, will serve as the co-principal clinical center and co-clinical lead.
08/
Abogen Biosciences Launches Phase 1 Clinical Trials for Two Novel mRNA Vaccines
Recently, Qiming Venture Partners portfolio company Abogen Biosciences announced that two independently developed novel mRNA vaccines — a lyophilized respiratory syncytial virus (RSV) vaccine (code: ABO1105) and a lyophilized varicella-zoster virus (VZV) vaccine (code: ABO1108) — have sequentially launched Phase 1 clinical trials in Guangxi.
Both ABO1105 and ABO1108 employ Abogen Biosciences' proprietary base modification technology, which overcomes Nobel Prize-level patent barriers, and the company's proprietary lipid nanoparticle (LNP) delivery system. The core component of this system is China's only ionizable lipid validated through large-scale Phase 3 clinical trials and protected by independent intellectual property rights.
Both vaccines also utilize Abogen Biosciences' mature lyophilized formulation process, enabling stable storage at 2-8°C for over two years with excellent stability, storage convenience, and accessibility. They are expected to provide safer and more effective vaccine solutions for the prevention of RSV and VZV infections.
Additionally, both leverage Abogen Biosciences' proprietary protein structure and RNA sequence design platform. Through optimized mutation site combinations for protein structure engineering, codon optimization, and UTR screening, the mRNA sequences' immunogenicity and druggability are enhanced, with full independent intellectual property protection.
Corporate Development
01/
Mech-Mind Robotics Announces Official Opening of German Showroom
Recently, Qiming Venture Partners portfolio company Mech-Mind Robotics officially opened its showroom on Industriestrasse in Germering, Munich, Germany.
This intelligent space spanning over 300 square meters integrates multiple functions including exhibition, training, warehousing, and conferencing. Leveraging its prime location in the industrial core zone and cutting-edge technical facilities, it provides more efficient technical support and service experiences for European, particularly German, customers — accelerating the scaled deployment of AI + robotics technology across more scenarios.
To enhance deployment efficiency for local partners, Mech-Mind Robotics' German subsidiary has established a technical training center. Using a combined "theory + hands-on" and "online + offline" approach, it helps users rapidly master AI vision debugging and complex problem-solving capabilities.
02/
YaoYing Medical Establishes CAR-T Cell Therapy International Consultation Center
Recently, Qiming Venture Partners portfolio company YaoYing Medical announced the official unveiling of its CAR-T Cell Therapy International Consultation Center at Shanghai YaoYing Hospital. The launch of this world-class clinical platform signals China's entry into the top tier of global cell therapy, opening a lifeline "from despair to rebirth" for hematological cancer patients and reshaping the global healthcare landscape through "international medicine, Chinese innovation."
YaoYing Medical has established a dedicated CAR-T rapid response team led by the medical director, with active participation from hematology, general internal medicine, inpatient services, ICU, nursing, laboratory medicine, radiology, pharmacy, patient services, insurance, and other departments. The team has also partnered with public hospital specialists from the Ruijin Medical Alliance and Tongji CAR-T Alliance to develop comprehensive emergency protocols. All issues are coordinated and resolved in real time to help patients safely navigate every challenge.
Leveraging its technical strengths and cost-effectiveness, YaoYing Medical has successfully treated 12 international patients from New Zealand, Southeast Asia, and European countries within just one year. Multiple international patients have been discharged following treatment, with follow-up results showing favorable recovery across all indicators.
Product Launches
01/
UBTECH Co-Develops First Household
Desktop AI Robot, Nationwide Launch
Recently, China Telecom Shaanxi Branch and Digital Life Company partnered with Qiming Venture Partners portfolio company UBTECH (09880.HK) to co-develop the first "household desktop AI robot," now officially launched nationwide. This innovative achievement marks a new phase in the application of humanoid robots for home companionship, opening a new chapter in intelligent home living.
In this development, UBTECH's full-stack humanoid robot technology was combined with China Telecom's cloud-network integration capabilities, built on China Telecom's large model foundation, further enhancing the robot's intelligence and scenario adaptability. This desktop robot delivers personalized intelligent recommendations, multimodal emotional computing, and intelligent guardianship through deep AI support, while also integrating with other smart home devices to deliver a comprehensive intelligent experience for children and parents alike. Its launch successfully fills the gap in the home companion humanoid robot market, redefining the form and interaction model of home intelligent terminals and truly realizing a "knows you better" smart home life.
02/
Shangyue Releases Intelligent Procurement Platform R7
Recently, Qiming Venture Partners portfolio company Shangyue officially released its intelligent procurement platform R7, deeply integrating artificial intelligence with procurement operations to open a new paradigm in procurement digitalization.
Shangyue's intelligent procurement platform R7 adopts a four-layer architecture design comprising cloud-native infrastructure (IaaS), PaaS, SaaS, and BaaS layers. This release features two major highlights: first, the debut of the Qianji AI intelligent engine at the PaaS layer; and second, at the BaaS layer, not only the completion of existing full-chain applications but also the innovative integration of a series of AI Agent applications.
03/
HyperStrong Unveils MagicBlock Platform
and HyperBlock M
At the European Smart Energy Expo, Qiming Venture Partners portfolio company HyperStrong (688411.SH) launched the MagicBlock platform, along with its HyperBlock M product.
The MagicBlock platform breaks through the limitations of individual cells or PCS units, offering a flexible system architecture that can be freely configured according to project requirements. It is broadly applicable to scenarios including renewable energy grid integration, frequency regulation and peak shaving, and standalone energy storage stations.
HyperBlock M represents a profound transformation in energy storage system design philosophy. Built around people, scenarios, and performance, it abandons the traditional battery-centric mindset, incorporating portability, modularity, and intelligent monitoring to precisely address the real-world demands of the global energy storage market.
04/
Pulnovo Medical Pulmonary Artery Radiofrequency Ablation System
Receives European Market Authorization
On the opening day of the EuroPCR conference, the pulmonary artery radiofrequency ablation system from Qiming Venture Partners portfolio company Pulnovo Medical successfully passed EU Medical Device Regulation (MDR) certification review, marking Pulnovo Medical's second CE-MDR certification in 2025. In March of this year, Pulnovo Medical's PADN catheter received EU CE-MDR certification, signaling that the company's core products now hold the passport for entry into the European market.
With this, Pulnovo Medical's PADN "system + catheter" product suite has completed full registration and certification under EU MDR standards, equipping it with global market competitiveness. This achievement not only validates the international advanced level of Pulnovo Medical's product design, but also demonstrates the company's deep accumulation in compliance, quality systems, and clinical data development.
05/ Jacobio Pharma's KRAS G12C Inhibitor Aireka® Approved for Market
Recently, the National Medical Products Administration (NMPA) website showed that the KRAS G12C inhibitor Aireka® (generic name: glecirasib), independently developed by Qiming Venture Partners portfolio company Jacobio Pharma (01167.HK), has been officially approved for market, with an indication for KRAS G12C-mutated non-small cell lung cancer in patients who have received at least one systemic therapy. This approval triggers milestone payment conditions, and Jacobio Pharma will receive a RMB 50 million milestone payment from partner Shanghai Allist Pharmaceuticals.
Dr. Yinxiang Wang, Chairman and CEO of Jacobio Pharma, stated: "The successful market launch of glecirasib marks Jacobio Pharma's formal transition from early-stage R&D into commercialization. Behind this breakthrough is our team's decade-long, unwavering commitment to tackling difficult drug targets. We will use the commercialization of glecirasib as our starting point to accelerate the realization of value from our subsequent pipeline."
Technology Strength
01/ AXera M57 Series Chips
Pass ASIL B/D Functional Safety Product Certification
Recently, international testing, inspection, and certification body DEKRA awarded Qiming Venture Partners portfolio company AXera the ASIL B/D functional safety product certification for its automotive M57 series chips. This marks another important advance in the safety and reliability of AXera's automotive chips, providing solid assurance for the M57 series' application in the global assisted driving market.
This certification marks another milestone for AXera, following its ISO 26262:2018 ASIL D functional safety process certification and M76H chip ASIL B functional safety product certification in January 2024, and its "NPU Toolchain Pulsar2" TCL3 automotive functional safety toolchain certification in December 2024. It signifies that the M57 series SoC's functional safety architecture, design implementation, and safety coverage meet the internationally recognized automotive functional safety standard ISO 26262 ASIL B/D requirements, achieving world-class standards. It also demonstrates that AXera's M57 series SoC products can provide safety assurance for ADAS applications, meeting the functional safety development and application requirements of top-tier global automakers and Tier 1 suppliers.
02/ DeepWay Delivers First Batch of 30 New Energy Heavy-Duty Trucks to Heibao Logistics
Recently, Qiming Venture Partners portfolio company DeepWay successfully delivered its first batch of 30 new energy heavy-duty trucks to Heibao Logistics, a leading Chinese less-than-truckload (LTL) logistics enterprise, helping launch China's first dedicated new energy LTL logistics network. This delivery represents another major breakthrough for DeepWay in the LTL logistics sector and reflects Heibao Logistics' firm commitment to advancing green, low-carbon transportation.
DeepWay's heavy-duty trucks adhere to a forward-design philosophy, driving market breakthroughs through continuous technological innovation. In just two years, DeepWay has cumulatively delivered over 4,500 intelligent new energy heavy-duty trucks across China, covering more than 20 provinces and municipalities, and has secured hundred-unit-level orders in multiple regions. The vehicles delivered in this batch will primarily be deployed on routes from Zhengzhou, Henan to various destinations within Henan as well as neighboring provinces including Hebei, Anhui, Jiangsu, and Hubei. They can achieve a maximum daily range of 670 kilometers, with power consumption as low as 1.1 kWh per kilometer, reducing comprehensive operating costs by approximately 30% or more compared to previous alternatives.
03/
Pulis Biotech Presents at WHA78 Thematic Seminar and High-Level Side Event
During the 78th World Health Assembly (WHA78), Tsinghua University's Vanke School of Public Health and the Geneva Health Forum co-hosted a thematic seminar on "China's Medical Technology Innovation and Its Impact on Global Health." Qiming Venture Partners portfolio company Pulis Biotech was invited to participate as a representative of China's molecular diagnostic technology innovators. Pulis Biotech founder and chief scientist Professor Song Yangzhou delivered a speech, sharing how near-patient molecular diagnostic technology can empower primary healthcare systems and improve diagnostic equity and accessibility.
During WHA78, a high-level side event titled "Innovation in Financing and New Technologies to End TB" was held in Geneva, Switzerland, co-hosted by the Stop TB Partnership and Health Innovation Exchange. In the "Innovation in Action Panel" thematic discussion, Professor Song Yangzhou introduced Pulis Biotech's near-patient molecular diagnostic platform MiniDock, designed for primary healthcare systems. The platform supports both sputum and tongue swab samples, with results available in 5–25 minutes and manual operation time of only 1–2 minutes. It requires no cold chain or laboratory conditions and is suitable for diverse scenarios within primary service networks. Tongue swabs serve as a supplementary sampling method for individuals unable to provide sputum samples (such as children, elderly patients, and immunocompromised populations), expanding the applicability and coverage of tuberculosis detection in primary healthcare systems.
Professor Song Yangzhou noted that the challenge of tuberculosis cannot be solved by technology alone; coordinated mechanisms must be established between diagnosis, policy, financing, and service systems. "My team and I have always hoped to bring tangible improvements to society through technological innovation—not just enhancing diagnostic efficiency, but bringing more equitable and accessible health protection to more people."
04/
DeepWise Co-Developed Science Navigator Platform Officially Launches, Empowering Peking University Researchers to Explore Academic Frontiers
Recently, Science Navigator — a next-generation AI4S research knowledge base and AI academic search platform jointly developed by the AI for Science Institute, Beijing and Qiming Venture Partners portfolio company DeepWise — was officially launched.
This is the world's first AI research platform covering the full spectrum of "reading literature — conducting computations — performing experiments — multidisciplinary collaboration," empowering scientific research innovation through intelligent technology. It helps Peking University researchers efficiently explore academic frontiers, freeing scientists from tedious information searches so they can devote more energy to genuine research breakthroughs.
05/
Benewake Showcases at SLAS Europe, Flagship Conference for Global Laboratory Automation and Biotechnology
At SLAS Europe, the flagship conference for global laboratory automation and biotechnology, Qiming Venture Partners portfolio company Benewake presented its full-stack intelligent automation products.
Benewake showcased three core products: the LabMate Gleam series pipetting assistant, the LabMate Polar series transport assistant, and the Bioyond Studio® laboratory automation software.
Leveraging its deep hardware-software integration capabilities, Benewake continues to expand its global business footprint while maintaining its advantages in core European and American markets. Over the past six months, Benewake has accelerated multi-regional collaborative expansion, completing initial deployments in emerging markets including Japan, South Korea, and Southeast Asian countries, steadily building momentum for its globalization strategy.
Corporate Honors
01/ Over a Dozen Qiming Venture Partners Portfolio Companies Named to China Healthcare Industry Investment and Financing Honor Roll
Recently, the 2024 China Healthcare Industry Investment and Financing Honor Roll, jointly presented by CHC Healthcare Consulting and CITIC Securities, was officially announced. This annual list covers investment institutions, individual investors, and enterprises. Qiming Venture Partners and its portfolio companies received multiple awards.
In the enterprise categories, Qiming Venture Partners portfolio companies Shukun Technology, Cornerstone Robotics, Northsea Life Sciences, Tupu Medical, Jialiang Medical, and Dingke Medical were named to the Top 50 Most Influential Healthcare Enterprises. Shengene Biotech, Yinzheng Gene, Tichem Bio, ACX Instruments, and Shize Biotech were named to the Top 50 Most Investment-Worthy Healthcare Enterprises. Torus Future, Ontime Micro, and Ze'an Biopharmaceutical were named to the Top 20 Best Emerging Healthcare Enterprises.
02/ Shengshu Technology Wins Major Award at 4th New Audio-Visual Integration Innovation and Creativity Competition
At the 5th China (Beijing) Radio and Television Media Integration Development Conference, Qiming Venture Partners portfolio company Shengshu Technology won first prize in the industry innovation track of the "4th New Audio-Visual Integration Innovation and Creativity Competition" for its core technologies and industrial application achievements in AI video generation, and was successfully selected for the "Beijing Audio-Visual Integration Excellent Industry Innovation Project Library."
This marks Shengshu Technology's industry-wide recognition for its technical innovation and commercial execution in AI-powered audio-visual content, underscoring its pivotal role in transforming how audio-visual content is produced.
Past Issues
Qiming Weekly | Qiming Venture Partners Portfolio Updates Vol. 17, 2025
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds with total committed capital of $9.5 billion. Since its inception, the firm has focused on investing in outstanding early- and growth-stage companies in the Technology and Consumer (T&C) and Healthcare sectors.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have listed on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many companies in Qiming Venture Partners' portfolio have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ: BILI, 09626.HK), Zhihu (NYSE: ZH, 02390.HK), Roborock (688169.SH), UBTECH (09880.HK), WeRide (NASDAQ: WRD), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ: ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ: SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Berry Genomics (000710.SZ), Sinocelltech (688520.SH), Yuanxin Technology, ClinChoice, Belief BioMed, Biren Technology, and others.